A humanized monoclonal antibody targeting CD39 with novel mechanism for cancer treatment

Autor: Wei, Zheng, Ren, Fang, Gong, Shiyong, Shi, Beilei, Ouyang, Kedong, Wu, Chengbin

Publikováno v: In Medicine in Drug Discovery September 2021 11

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

A novel designed anti-PD-L1/OX40 bispecific antibody augments both peripheral and tumor-associated immune responses for boosting anti-tumor immunity.

Autor: Li B; Epimab Biotherapeutics, Shanghai, China., Gong S; Epimab Biotherapeutics, China., Zhang N; Epimab Biotherapeutics, shanghai, China., Shi B; Epimab Biotherapeutics, China., Lv Z; Epimab Biotherapeutics, China., Zhang Y; Epimab Biotherapeutics, China., Gaowa N; Epimab Biotherapeutics, China., Dong L; Epimab Biotherapeutics, China., Wu D; Epimab Biotherapeutics, Shanghai, China., Wu J; Epimab Biotherapeutics, China., Liu F; Epimab Biotherapeutics, China., Zhang R; Epimab Biotherapeutics, China., Behzadigohar R; Peninsula and Southeast Oncology, Australia., Ganju V; Hudson Institute of Medical Research, melbourne, victoria, Australia., Wu C; Epimab Biotherapeutics, Shanghai, China., Wu X; Epimab Biotherapeutics, Shanghai, China.

Publikováno v: Molecular cancer therapeutics [Mol Cancer Ther] 2024 Nov 22. Date of Electronic Publication: 2024 Nov 22.